BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dexmedetomidine (Igalmi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dexmedetomidine (Igalmi)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06335407-9509@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270227
DTEND;VALUE=DATE:20270228
SUMMARY:Dexmedetomidine (Igalmi): Phase 1 readout est. (NCT06335407)
DESCRIPTION:Dexmedetomidine (Igalmi)\, phase 1.\nStudy: Effect of Sublingua
 l Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatien
 t Study\nEstimated primary completion: 27 February 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dexmedetomidine-igalmi#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06335407
URL:https://assetmemo.bio/drug/dexmedetomidine-igalmi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025605-9509@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dexmedetomidine (Igalmi): Phase 1 readout est. (NCT05025605)
DESCRIPTION:Dexmedetomidine (Igalmi)\, phase 1\, Schizophrenia.\nStudy: Det
 ermining Efficacy and Safety of BXCL501 in Agitation Associated With Pedia
 tric Schizophrenia and Bipolar Disorder\nEstimated primary completion: 31 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dexmedetom
 idine-igalmi#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05025605
URL:https://assetmemo.bio/drug/dexmedetomidine-igalmi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
